Personalised Integrated Biomaterial Risk Assessment (PANBIORA)

Biomaterials are becoming increasingly important in the medical field, e.g. as implant materials. In the EU project PANBIORA, a modular system was developed to predict the patient-specific reaction to a specific biomaterial.

Standardized biomaterial assessment opens the space for personalized preimplantation diagnostics. PANBioRA allowed for the first time to predict a patient's response to a specific biomaterial before it is implanted. These measures allow selection of the best material, minimize side effects and improve health outcomes.

The PANBioRA testing system allows for improved, faster and more cost-effective evaluation of biomaterials. In the first project period, the focus was on the further development of the PANBioRA system and the linking of the different components. In addition, the first version of a risk assessment system based on multi-criteria decision analysis was developed. Clinical samples were collected and tested, and initial planning steps were taken for the commercial launch of the prototype.

With the completion of the second reporting period, the project received excellent feedback from the European Commission, which stated that "some of the specific research tasks have a very strong innovation potential that will undoubtedly be welcomed by stakeholders involved in the risk management of new nano-biomaterials." The final phase of the project also focussed on the exploitation of the knowledge gathered and possible patent applications.

As project coordinator, Steinbeis Europa Zentrum was responsible for administrative project coordination, communication, dissemination of project results and IPR management.

Further information:

• Project name acronym: PANBioRA
• Funding: European Commission, Horizon 2020
• Funding budget for all partners: 8 Mio. EUR
• Participating countries: Albania, Belgium, Czech Republic, Estonia, Finland, France, Germany, Ireland, Serbia, Spain, UK
• Project duration: 01/2018 – 12/2021